학술논문
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
Document Type
Article
Author
Voorhees, Peter M ; Sborov, Douglas W; Laubach, Jacob; Kaufman, Jonathan L; Reeves, Brandi; Rodriguez, Cesar; Chari, Ajai; Silbermann, Rebecca; Costa, Luciano J; Anderson, Larry D, Jr; Nathwani, Nitya; Shah, Nina; Bumma, Naresh; Efebera, Yvonne A; Holstein, Sarah A; Costello, Caitlin; Jakubowiak, Andrzej; Wildes, Tanya M; Orlowski, Robert Z; Shain, Kenneth H; Cowan, Andrew J; Dinner, Shira; Pei, Huiling; Cortoos, Annelore; Patel, Sharmila; Lin, Thomas S; Usmani, Saad Z; Richardson, Paul G
Source
In The Lancet Haematology October 2023 10(10):e825-e837
Subject
Language
ISSN
2352-3026